Published in Nutr Cancer on November 18, 2011
Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate (2014) 1.47
Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog (2013) 1.11
Associations of tea and coffee consumption with prostate cancer risk. Cancer Causes Control (2013) 0.94
Going Green: The Role of the Green Tea Component EGCG in Chemoprevention. J Carcinog Mutagen (2013) 0.93
Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice. PLoS One (2015) 0.92
Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells. J Cancer Res Clin Oncol (2012) 0.92
Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90
Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila) (2015) 0.83
The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) (2012) 0.81
(-)-Epigallocatechin-3-gallate (EGCG) attenuates functional deficits and morphological alterations by diminishing apoptotic gene overexpression in skeletal muscles after sciatic nerve crush injury. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.80
Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2014) 0.79
Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control (2013) 0.79
Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials (2012) 0.78
Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells. PLoS One (2015) 0.75
Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget (2016) 0.75
Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control (2013) 0.75
Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review. Int Braz J Urol (2016) 0.75
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem (2016) 0.75
Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. Antioxidants (Basel) (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Cancer cell cycles. Science (1996) 21.29
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (1995) 15.07
Tumor angiogenesis. N Engl J Med (2008) 11.30
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev (1995) 9.31
Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol (1993) 6.53
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst (2000) 5.77
Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst (1997) 5.07
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr (2003) 3.75
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med (1997) 3.59
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol (1999) 3.06
Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol (1999) 2.91
p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta (2000) 2.81
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res (2003) 2.80
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A (2001) 2.79
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene (2006) 2.60
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 2.58
Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr (2000) 2.52
The chemistry of tea flavonoids. Crit Rev Food Sci Nutr (1997) 2.51
Tea polyphenols for health promotion. Life Sci (2007) 2.50
Carcinoma of the prostate. N Engl J Med (1991) 2.47
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
Biology of prostate-specific antigen. J Clin Oncol (2003) 2.44
The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res (2001) 2.44
Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol (2006) 2.41
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst (1997) 2.39
Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal (2008) 2.36
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology (1999) 2.30
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev (2002) 2.29
Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol (1999) 2.21
Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat (2007) 2.21
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res (2005) 2.07
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A (2000) 2.04
Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem (2003) 2.01
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
NF-kappaB as a potential molecular target for cancer therapy. Biofactors (2007) 1.93
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev (2001) 1.87
Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev (1998) 1.87
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate (2002) 1.86
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res (2004) 1.84
Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer (2004) 1.80
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology (2000) 1.72
Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev (1995) 1.70
Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos (1997) 1.69
Antimicrobial properties of tea (Camellia sinensis L.). Antimicrob Agents Chemother (1995) 1.69
Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis (2005) 1.66
Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys (2000) 1.63
Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene (2003) 1.62
IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia (2008) 1.62
p21--negative regulator of the cell cycle. Proc Soc Exp Biol Med (1996) 1.61
Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol (2006) 1.61
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2007) 1.58
Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene (2007) 1.57
Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) (2009) 1.56
Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol (2000) 1.55
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res (2003) 1.50
Systematic review: green tea and gastrointestinal cancer risk. Aliment Pharmacol Ther (2004) 1.49
A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res (2003) 1.48
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr (2002) 1.48
Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett (1995) 1.48
Cell cycle and apoptosis. Neoplasia (2001) 1.47
Tea in chemoprevention of cancer. Int J Oncol (1996) 1.47
Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res (2003) 1.46
Molecular targets for green tea in prostate cancer prevention. J Nutr (2003) 1.43
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42
Agents in development for prostate cancer prevention. Expert Opin Investig Drugs (2004) 1.42
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun (1996) 1.40
High-grade prostatic intraepithelial neoplasia. Mod Pathol (2004) 1.40
Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys (2003) 1.39
Green tea and cancer in humans: a review of the literature. Nutr Cancer (1998) 1.39
Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev (2003) 1.38
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine (2010) 1.37
Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene (2004) 1.36
Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci (2004) 1.36
Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol (2001) 1.36
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol (2001) 1.33
Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol (2010) 1.31
Cell-cycle control in the face of damage--a matter of life or death. Trends Cell Biol (2009) 1.30
Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate (2007) 1.29
Tea and cancer prevention: epidemiological studies. Pharmacol Res (2011) 1.27
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2010) 2.40
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol (2003) 1.21
Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev (2004) 1.12
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev (2012) 0.98
Lycopene in the prevention of prostate cancer. J Soc Integr Oncol (2008) 0.97
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med (2003) 0.93
Antibody functionalized interdigitated micro-electrode (IDmicroE) based impedimetric cortisol biosensor. Analyst (2010) 0.90
Dithiobis(succinimidyl propionate) modified gold microarray electrode based electrochemical immunosensor for ultrasensitive detection of cortisol. Biosens Bioelectron (2010) 0.86
Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs (2011) 0.85
Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol (2010) 0.84
A Realtime and Continuous Assessment of Cortisol in ISF Using Electrochemical Impedance Spectroscopy. Sens Actuators A Phys (2011) 0.82
Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2014) 0.79
Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med (2013) 0.76
Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control (2013) 0.75
Chemoprevention in African American Men With Prostate Cancer. Cancer Control (2016) 0.75